These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

290 related items for PubMed ID: 34372769

  • 1. Clinical and virological outcomes with baloxavir compared with oseltamivir in pediatric patients aged 6 to < 12 years with influenza: an open-label, randomized, active-controlled trial protocol.
    Ishiguro N, Morioka I, Nakano T, Furukawa M, Tanaka S, Kinoshita M, Manabe A.
    BMC Infect Dis; 2021 Aug 09; 21(1):777. PubMed ID: 34372769
    [Abstract] [Full Text] [Related]

  • 2. Baloxavir Marboxil Single-dose Treatment in Influenza-infected Children: A Randomized, Double-blind, Active Controlled Phase 3 Safety and Efficacy Trial (miniSTONE-2).
    Baker J, Block SL, Matharu B, Burleigh Macutkiewicz L, Wildum S, Dimonaco S, Collinson N, Clinch B, Piedra PA.
    Pediatr Infect Dis J; 2020 Aug 09; 39(8):700-705. PubMed ID: 32516282
    [Abstract] [Full Text] [Related]

  • 3. Early treatment with baloxavir marboxil in high-risk adolescent and adult outpatients with uncomplicated influenza (CAPSTONE-2): a randomised, placebo-controlled, phase 3 trial.
    Ison MG, Portsmouth S, Yoshida Y, Shishido T, Mitchener M, Tsuchiya K, Uehara T, Hayden FG.
    Lancet Infect Dis; 2020 Oct 09; 20(10):1204-1214. PubMed ID: 32526195
    [Abstract] [Full Text] [Related]

  • 4. Clinical efficacy and safety of baloxavir marboxil in the treatment of influenza: A systematic review and meta-analysis of randomized controlled trials.
    Kuo YC, Lai CC, Wang YH, Chen CH, Wang CY.
    J Microbiol Immunol Infect; 2021 Oct 09; 54(5):865-875. PubMed ID: 34020891
    [Abstract] [Full Text] [Related]

  • 5. Duration of fever and symptoms in children after treatment with baloxavir marboxil and oseltamivir during the 2018-2019 season and detection of variant influenza a viruses with polymerase acidic subunit substitutions.
    Saito R, Osada H, Wagatsuma K, Chon I, Sato I, Kawashima T, Saito T, Kodo N, Ono Y, Shimada Y, Phyu W, Shobugawa Y.
    Antiviral Res; 2020 Nov 09; 183():104951. PubMed ID: 32987032
    [Abstract] [Full Text] [Related]

  • 6. Virological and clinical outcomes in outpatients treated with baloxavir or oseltamivir: A Japanese multicenter study in the 2019-2020 influenza season.
    Chong Y, Kawai N, Tani N, Bando T, Takasaki Y, Shindo S, Ikematsu H.
    Antiviral Res; 2021 Aug 09; 192():105092. PubMed ID: 34052230
    [Abstract] [Full Text] [Related]

  • 7. Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents.
    Hayden FG, Sugaya N, Hirotsu N, Lee N, de Jong MD, Hurt AC, Ishida T, Sekino H, Yamada K, Portsmouth S, Kawaguchi K, Shishido T, Arai M, Tsuchiya K, Uehara T, Watanabe A, Baloxavir Marboxil Investigators Group.
    N Engl J Med; 2018 Sep 06; 379(10):913-923. PubMed ID: 30184455
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Duration of fever in children infected with influenza A(H1N1)pdm09, A(H3N2) or B virus and treated with baloxavir marboxil, oseltamivir, laninamivir, or zanamivir in Japan during the 2012-2013 and 2019-2020 influenza seasons.
    Sun Y, Wagatsuma K, Saito R, Sato I, Kawashima T, Saito T, Shimada Y, Ono Y, Kakuya F, Minato M, Kodo N, Suzuki E, Kitano A, Chon I, Phyu WW, Li J, Watanabe H.
    Antiviral Res; 2024 Aug 06; 228():105938. PubMed ID: 38897317
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Baloxavir Marboxil in Japanese Pediatric Patients With Influenza: Safety and Clinical and Virologic Outcomes.
    Hirotsu N, Sakaguchi H, Sato C, Ishibashi T, Baba K, Omoto S, Shishido T, Tsuchiya K, Hayden FG, Uehara T, Watanabe A.
    Clin Infect Dis; 2020 Aug 14; 71(4):971-981. PubMed ID: 31538644
    [Abstract] [Full Text] [Related]

  • 14. Safety and effectiveness of baloxavir marboxil for the treatment of influenza in Japanese clinical practice: A postmarketing surveillance of more than 3000 patients.
    Nakazawa M, Hara K, Komeda T, Ogura E.
    J Infect Chemother; 2020 Jul 14; 26(7):729-735. PubMed ID: 32409018
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Baloxavir Marboxil for Prophylaxis against Influenza in Household Contacts.
    Ikematsu H, Hayden FG, Kawaguchi K, Kinoshita M, de Jong MD, Lee N, Takashima S, Noshi T, Tsuchiya K, Uehara T.
    N Engl J Med; 2020 Jul 23; 383(4):309-320. PubMed ID: 32640124
    [Abstract] [Full Text] [Related]

  • 17. Comparison of clinical efficacy and safety of baloxavir marboxil versus oseltamivir as the treatment for influenza virus infections: A systematic review and meta-analysis.
    Shiraishi C, Kato H, Hagihara M, Asai N, Iwamoto T, Mikamo H.
    J Infect Chemother; 2024 Mar 23; 30(3):242-249. PubMed ID: 37866622
    [Abstract] [Full Text] [Related]

  • 18. Pharmacokinetic and pharmacodynamic analysis of baloxavir marboxil, a novel cap-dependent endonuclease inhibitor, in a murine model of influenza virus infection.
    Ando Y, Noshi T, Sato K, Ishibashi T, Yoshida Y, Hasegawa T, Onishi M, Kitano M, Oka R, Kawai M, Yoshida R, Sato A, Shishido T, Naito A.
    J Antimicrob Chemother; 2021 Jan 01; 76(1):189-198. PubMed ID: 33035324
    [Abstract] [Full Text] [Related]

  • 19. Comparison of Household Transmission of Influenza Virus From Index Patients Treated With Baloxavir Marboxil or Neuraminidase Inhibitors: A Health Insurance Claims Database Study.
    Komeda T, Takazono T, Hosogaya N, Ogura E, Fujiwara M, Miyauchi H, Ajisawa Y, Iwata S, Watanabe H, Honda K, Kitanishi Y, Hara K, Mukae H.
    Clin Infect Dis; 2021 Jun 01; 72(11):e859-e867. PubMed ID: 33103200
    [Abstract] [Full Text] [Related]

  • 20. Comparison of Hospitalization Incidence in Influenza Outpatients Treated With Baloxavir Marboxil or Neuraminidase Inhibitors: A Health Insurance Claims Database Study.
    Komeda T, Takazono T, Hosogaya N, Miyazaki T, Ogura E, Iwata S, Miyauchi H, Honda K, Fujiwara M, Ajisawa Y, Watanabe H, Kitanishi Y, Hara K, Mukae H.
    Clin Infect Dis; 2021 Sep 07; 73(5):e1181-e1190. PubMed ID: 33354728
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.